Evidence map›Paper›PMID 33659241›Full record

ArticleFrontiers in bioengineering and biotechnology2021

Zoledronic Acid-Loaded Hybrid Hyaluronic Acid/Polyethylene Glycol/Nano-Hydroxyapatite Nanoparticle: Novel Fabrication and Safety Verification.

Yan Xu, Zheng Zhang, Hehui Wang, Wu Zhong, Chengmei Sun, Wei Sun, Hongwei Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Nanotechnology applications in rheumatology.Rheumatology international · 2022
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Innovative Biomaterials for the Treatment of Bone Cancer.International journal of molecular sciences · 2021
    Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Yan XuDepartment of Thoracic Medicine Oncolog, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Zheng ZhangZhejiang University-University of Edinburgh Institute, School of Medicine, Zhejiang University, Haining, China.
Hehui WangDepartment of Orthopedics, Ningbo Yinzhou Second Hospital, Ningbo, China.
Wu ZhongDepartment of Orthopedics, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Chengmei SunZhejiang University-University of Edinburgh Institute, School of Medicine, Zhejiang University, Haining, China.
Wei SunZhejiang University-University of Edinburgh Institute, School of Medicine, Zhejiang University, Haining, China.
Hongwei WuZhejiang University-University of Edinburgh Institute, School of Medicine, Zhejiang University, Haining, China.
Zhejiang University-University of Edinburgh Institute · CNCentral South University · CNHunan Cancer Hospital · CNNingbo No. 2 Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma is a malignant tumor that often occurs in adolescents and children. Zoledronic acid, a new-generation bisphosphonate, has been widely used as an antitumor drug to inhibit bone metastasis. However, the rapid renal elimination results in low effective concentrations. Meanwhile, high-dose intravenous zoledronic acid administration leads to severe side effects. The present study fabricated an organic-inorganic hybrid nanoparticle as the carrier of zoledronic acid. The rod-like nanoparticle, which had 150-nm length and 40-nm cross-sectional diameter, consisted of a hyaluronic acid/polyethylene glycol (HA-PEG) polymer shell and a nano-hydroxyapatite (nHA) core, with zoledronic acid molecules loading on the surface of nHA and clearance of HA-PEG shell. The nanoparticle was characterized by microscopic analysis,

Indexed as

cytotoxicitydrug releasehybridimmune responsenanoparticlezoledronic acid

Identifiers

PMID33659241
PMCPMC7917242
OpenAlexW3129556418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.